Skip to content
Screener

Maze Therapeutics MAZE Enterprise value

Enterprise value at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$120.2B+7.2%
Septerna, Inc. logo
Septerna, Inc.SEPN
$1.45B+363%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$1.77B+1,855%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$1.25B+502%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$1.83B+157%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$5.84B+181%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$48.0M-31.7%
Net income-$44.7M-32.8%
EPS (diluted)-$0.76+1.3%

Balance sheet

See full
Cash & equivalents$202.6M-23.4%
Total debt$60.4M+142%
Total equity$453.1M+72.8%
Total assets$531.6M+75.2%

Cash flow

See full
Operating cash flow-$15.1M+49.9%
CapEx$107.0K-72.8%
Free cash flow-$15.2M+50.2%

Valuation

See full
Market cap$1.51B+156%

Returns & leverage

See full
Return on equity-37.3%
Debt / equity0.1×0.0×
Current ratio18.3×+4.7×

Where this comes from

Calculated from Maze Therapeutics’s reported figures.

The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:48 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344903

FAQ

What is Maze Therapeutics's enterprise value?
Maze Therapeutics (MAZE) reported enterprise value of $1.51B in Q2 2026.
How has Maze Therapeutics's enterprise value changed year-over-year?
Maze Therapeutics's enterprise value increased by 608.9% year-over-year, from $212.89M to $1.51B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about Maze Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude